A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

NCT05327647 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Non-Muscle Invasive Bladder Cancer

Interventions

DRUG: Bicalutamide
BIOLOGICAL: Control Arm

Sponsor

CHU de Quebec-Universite Laval

Collaborators

[object Object]
[object Object]